Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark Scrutiny

The Bombay High Court has restrained Gleck Pharma from using XIGAMET for its diabetes product, finding it deceptively similar to Glenmark’s ZITA-MET. This decision highlights the Court’s heightened scrutiny in pharmaceutical trademark cases to prevent consumer confusion and associated health risks.

Read more about Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark Scrutiny